5 - 替代皮里丁-2,4-二碳酸盐衍生物具有选择性抑制人类Jumonji-C域含蛋白5的潜力
Lennart Brewitz1, Yu Nakashima1, Sonia K Piasecka2
1Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, OX1 3TA Oxford, U.K.
Journal of medicinal chemistry
|August 1, 2023
概括
研究人员开发了新的5-aminoalkyl-substituted 2,4-PDCA衍生物,可以选择性地抑制Jumonji-C域含蛋白5 (JMJD5). 这些强大的JMJD5抑制剂为研究其在发育,昼夜节律和癌症中的作用提供了宝贵的工具.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 含有 Jumonji-C 域的蛋白 5 (JMJD5) 是一种依赖于 2 氧格酸盐 (2OG) 的氧酶,涉及发育,昼夜节律和癌症.
- 它的确切作用机制尚不清楚,尽管有报道的活动,包括组蛋白酶,Nε-甲基氨酸脱甲基酶和氨酸残留基酶功能.
- 选择性小分子抑制剂对于剖析JMJD5的 (病理) 生理学作用至关重要.
研究的目的:
- 确定和描述JMJD5.5的强效和选择性小分子抑制剂.
- 研究这些抑制剂与JMJD5.5的结合相互作用.
- 评估化合物的细胞效应与已知JMJD5变体的关系.
主要方法:
- 合成和表征5-氨基基替代二二,4-二碳酸 (2,4-PDCA) 衍生物.
- 酶抑制测试以确定对人类2OG氧化酶的强度和选择性.
- 结晶学分析以阐明与抑制剂结合的JMJD5结构.
- 细胞测试以评估化合物的表型效应.
主要成果:
- 开发了基于2,4-PDCA支架的强效JMJD5抑制剂,与其他2OG氧酶相比具有显著的选择性.
- 结晶学研究揭示了诱导的适合结合,并详细说明了JMJD5基质结合口袋内的C5替代剂的方向.
- 细胞研究表明,在减少催化活性的JMJD5变体中观察到的化合物复印效应.
结论:
- 5-aminoalkyl-2,4-PDCA衍生物代表了一类有前途的选择性JMJD5抑制剂.
- 结构洞察力为进一步的抑制剂优化提供了基础.
- 这些抑制剂作为有价值的化学探针,用于探索生物系统中的JMJD5功能.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Enzyme Inhibition
78.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.7K
Five-Membered Heterocyclic Aromatic Compounds: Overview
4.0K
Heterocyclic aromatic compounds are cyclic compounds that are aromatic and have one or more heteroatoms—atoms other than carbon, in the ring. Depending upon the number of atoms present in the ring, they can be either five or six-membered. Examples of five-membered heterocyclic aromatic compounds include pyrrole, furan, thiophene, and imidazole. Pyrrole consists of one nitrogen atom having one lone pair of electrons. Furan and thiophene have one oxygen and one sulfur heteroatom,...
4.0K
Eukaryotic Transcription Inhibitors
9.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K


